1
Appendix 1: Case-based learning exercise
Part 1 (5 minutes)
It is the winter of 2008 and Ted is a 51-year-old man who resides in a suburb of Los Angeles with his wife of 25 years and their four children. Ted owns and operates a small convenience store a few blocks from his home. Ted seeks help at an urgent care clinic for an illness consisting of fever, night sweats, myalgia, arthralgia and a sore throat that he has had for about a week.
Physical examination reveals non-tender lymphadenopathy involving the cervical lymph nodes, a mild fever and pharyngeal edema. He reports that he was previously in good health. Influenza season is in full swing and two of Ted's employees have been sent home with influenza-like symptoms. He indicates that he did not get an influenza shot this year. This year, influenza activity is widespread and he is given a prescription for oseltamivir (Tamiflu®). The clinic is offering free HIV testing and Ted opts to have his blood drawn for the test. Question 1. At this point in time, is therapy indicated for influenza for this patient?
A. No, the patient's symptoms are not severe and oseltamivir is not going to be optimally effective for this patient B. No, the patient's symptoms are not severe and oseltamivir should only be prescribed for patients with confirmed influenza C. No, the patient most likely does not have influenza; not every influenza-like illness during influenza season is influenza. Tell him to come back in a week if symptoms persist D. Yes, it is influenza season and he most likely has influenza. Oseltamivir will shorten the duration of illness in this patient and decrease transmission E. Yes, it is influenza season and he most likely has influenza. Oseltamivir should be given to anyone who has influenza-like symptoms Answer: A The patient's symptoms are not severe and oseltamivir is most effective within 24-48h of symptom onset as it has no effect on the course of disease when administered 48 h after the onset of symptom. Oseltamivir is a neuraminidase inhibitor and blocks free virus from infecting uninfected cells and it also decreases transmission. Oseltamivir is prescribed for those patients at high risk for complications from influenza.
Facilitation notes: Students typically have difficulty with this question, with several groups selecting B or D. This presents a nice learning opportunity for the clinician educators to help students think about what constitutes "severe symptoms", when treatment for influenza is warranted, and which patient populations are particularly vulnerable and should be treated. In addition, while students may be able to articulate the mechanism of action of oseltamivir, they may not easily make the connection that the drug is most effective within a brief window of time following infection. Facilitation notes: In our experience, these questions provide the students with an opportunity to understand how antibodies are used as diagnostic tools (ELISA, immunoblot, and later in the TBL flow cytometry). This knowledge is consistent with that described in the USMLE content outline with respect to the basis of immunologic diagnostics (e.g., antigen-antibody reactions used for diagnostic purposes, ELISA, immunoblotting, etc.). In addition, this is an excellent opportunity to differentiate between the "specificity" and "sensitivity" of ELISAs and immunoblotting.
Stop here 6 Part 6 (5 minutes) Question 9. How do you explain the finding that Ted's first HIV ELISA was negative but the second test was positive?
A. The first ELISA produced a false negative result B. Seroconversion requires about 6 weeks following HIV infection C. HIV viremia is only significant 4-5 weeks following HIV infection D. HIV antibodies are produced early in infection but are bound to the virus in the blood and cannot be detected until later in infection when they are produced in high quantities and can then be detected free in the patient's serum E. HIV antibodies are produced early in infection but are IgM and cannot be detected by the ELISA, which only detects IgG antibodies F. HIV antibodies are not produced early in infection because the virus causes a transient immunosuppression that is overcome later in infection Answer: B Seroconversion occurs within 4-6 weeks after HIV infection because an antibody response in an immunologically naïve host takes time to develop. The HIV ELISA is sensitive (able to detect small quantities of HIV-reactive antibodies) but not specific (cross-reactive antibodies can be found in people with CMV or influenza and result in a false positive test) whereas the Western blot is very specific (tells you which viral proteins the immune system is reacting to) but less sensitive. ELISA to detect free HIV in the blood (viremia) and viral load test to quantify HIV RNA in serum E.
Western blot to assess antibody response to HIV proteins (gp120, gp41, p24) and viral load test to quantify HIV RNA in serum
Answer: A The viral load test quantifies HIV RNA levels by RT-PCR (high sensitivity and high specificity). This test is a useful correlate to predict clinical outcome. The test quantifies the number of copies of HIV-1 RNA per ml of plasma and is an accurate reflection of the burden of infection and the magnitude of viral replication. It is used to assess the risk of disease progression and guides initiation of ART. Flow cytometry is used to quantify the concentration of CD4 + T cells in plasma. The CD4 T cell count indicates the patient's immune status. When T cell numbers drop below 200/ml of plasma, the patient will begin to exhibit constitutional symptoms and eventually progress to suffer from opportunistic diseases (often fungal) and death.
Question 13. Which test will you use to monitor Ted's immune status after he begins antiretroviral therapy?
A. Viral load test to quantify HIV RNA in serum B.
Flow cytometry to quantify CD4 cells C.
Flow cytometry to quantify number of HIV infected CD4 cells D.
ELISA to detect free HIV in the blood (viremia) E.
Western blot to assess antibody response to HIV proteins (gp120, gp41, p24)
Answer: B Flow cytometry is used to quantify the concentration of CD4+ T cells in plasma as a measure of the patient's immune status. The goal of HAART is to have a positive virologic (decrease viral load) and immunologic (increase CD4 cell numbers) effect by limiting HIV infection and killing of CD4 T cells.
Facilitation notes: Questions 12 and 13 are traditionally tough questions for students. Students are beginning to learn about virology in general and are often unclear as to how blood can be effectively used in disease diagnosis. For question 13, groups often select A or C, which seem plausible at this stage in their training, but are incorrect answers. This question can be used to guide students in thinking about which HIV viral components can be detected in blood, and why flow cytometry is an important HIV diagnostic tool.
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Part 10 (10 minutes) Question 14. What do you anticipate Ted's viral load and CD4 count to be? Use the graph to answer this question.
A. Viral load <1,000, CD4 <200 B.
Viral load <1,000, CD4 ∼1,000 C.
Viral load 10,000-50,000, CD4 <200 D.
Viral load 10,000-50,000, CD4 ∼1,000 E.
Viral load >100,000, CD4 <200 F.
Viral load >100,000, CD4 ∼500
Answer: F Early in infection HIV replicates rapidly and viremia is very high (>100,000 copies/mL and typically over a million copies/mL in the early phase versus 10,000-30,000 copies/mL in patients with an established HIV infection). In early HIV infection, there is a period of rapid HIV replication in CD4 T cells resulting in a transient, but marked drop in CD4 counts (<500/mL). Normal CD4 T cell levels are 500-1500/mL. HIV genotype testing F.
Initiate antimicrobial prophylaxis to prevent infection with opportunistic pathogens
Answer: E Genotyping identifies viral mutations in the HIV reverse transcriptase and protease genes that correlate with resistance to different antiretroviral drugs and is used to inform selection of appropriate antiretrovirals.
Facilitation notes: This question is challenging for students, and many groups want to start some form of treatment immediately (either A or F). Students also see some value in answer choice C, and understand that patients need to be ready for treatment and that this can take time. • In general, physicians may breach patient confidentiality in this situation and notify a sexual or needle sharing partner of an individual's HIV infection who is at identifiable risk of infection, as long as they act in good faith and offer only the information necessary to help the notified person protect against future risk of infection or seek medical treatment.
• These guidelines do not require that a physician disclose the name of the person who might be putting an individual at risk, although in some instances that identity will be obvious.
• These guidelines do not justify disclosures about HIV information to insurers, employers, schools, or other institutions.
• Efforts at contact tracing need not breach medical confidentiality with regard to the HIV positive person. They need only to advise people that they may have been exposed to HIV infection • In general, the local Department of Health will be involved in the identification and appropriate notification of at-risk individuals.
Source: http://www.ama-assn.org/ama/pub/physician-resources/medical-ethics/code-medicalethics/opinion223.page?
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Ted is referred to the infectious disease department for treatment of his HIV. Genotyping data confirm that his HIV is susceptible to all approved HIV antiretrovirals.
Question 17. How should Ted be treated?
A. Do not treat during at this time because it will induce the emergence of antiretroviral resistance B.
Do not treat until Ted's CD4 T cells drop to <500/mL C.
Prescribe one antiretroviral at a time. If the first is effective keep Ted on this drug alone and when resistance occurs, switch to another drug D.
Immediately begin treatment with two drugs in the same class to prevent disease progression and the emergence of resistance E.
Immediately begin treatment with three drugs, two in the same class and the third in a separate class to prevent disease progression and the emergence of resistance
Answer: E Highly-active antiretroviral therapy (HAART) is based on a combination of drugs that significantly reduce patient morbidity and mortality, allowing most patients a normal lifespan. Today HIV is considered a managed chronic infectious disease. The usual starting therapy is a 2 nucleoside-RT inhibitor backbone with an integrase inhibitor, a non-nucleoside RT inhibitor, or a protease inhibitor. These drugs target three major HIV antigens: RT, integrase and protease. There remains debate about whether to treat early, however most clinicians support early treatment.
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